Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist
Contact+90 (538) 677 60 18

Stomach-Protecting Drugs May Adversely Affect Survival in Glioblastoma

ContributorsAuthor · Medical review · Editorial approval
Published
Updated
4 min read
Stomach-Protecting Drugs May Adversely Affect Survival in Glioblastoma
In this article

An Overlooked Risk in Glioblastoma Treatment: Could "Harmless" Proton Pump Inhibitors Shorten Life?

Patients diagnosed with the aggressive brain tumor glioblastoma (GBM) routinely receive corticosteroids to reduce tumor-related swelling and pressure. To prevent steroid-related stomach irritation, almost everyone is also automatically prescribed stomach-protecting proton pump inhibitors (PPIs). In oncology, this is often done without question.

What if the drugs given to protect patients are actually protecting their tumors?

On 25 November 2025, JAMA Network Openpublished a large meta-analysis involving approximately 3000 patients that supports this alarming possibility. It found that certain stomach-protecting drugs, such as omeprazole and pantoprazole, accelerated progression and shortened overall survival in glioblastoma. It suggests we need to scrutinize our prescriptions.

Clinical Glossary: What You Need to Know
PPI (Proton Pump Inhibitors): The most potent acid-suppressing drug class, including omeprazole, pantoprazole and lansoprazole; commonly called stomach protectors.
PA-PPI (Potent ALDH1A1-Activating PPIs): The specific PPI group implicated by the study, particularly omeprazole and pantoprazole . These activate ALDH1A1, an enzyme protecting tumor cells.
ALDH1A1 (Aldehyde Dehydrogenase 1A1): A shield-like protein within cancer cells that protects against oxidative stress and chemotherapy. Greater activity means greater treatment resistance.
H2 Blockers and Antacids: Older acid-reducing drugs outside the PPI class, such as famotidine. The study found these safe.

Mechanism: How Can a Stomach Drug Protect a Brain Tumor?

The association involves a molecular interaction independent of the drug's gastric effects.

The Trojan Horse Effect: To withstand the toxic environment created by chemotherapy (temozolomide), cancer cells use ALDH1A1 . Certain PPIs, including omeprazole and pantoprazole, chemically superactivate this enzyme. A drug intended to prevent gastric bleeding therefore strengthens the cancer cell's shield, protecting it from chemotherapy.

Study Details: A Large Analysis of 3000 Patients

Led by Dr. Emilie Le Rhun at the University of Zurich, the team examined data from 5 major randomized trials involving 2981 newly diagnosed glioblastoma patients. Medication use and survival were compared using landmark analysis.

  • Patient Population: Median age 58; 62% male.
  • Medications: Patients were grouped by potent ALDH activators (omeprazole/pantoprazole) versus other gastric medications (H2 blockers/antacids).
  • Timing: Effects were assessed separately at treatment initiation, during treatment and in maintenance.

Analysis Results: PPI Use Poses a Risk

The following figures show how much higher risk was in PPI users than nonusers.

Progression Risk (PFS) Up to 31% Increase
HR: 1.31
Patients using PPIs at month 6 had substantially higher progression risk.
Risk of Death (Overall Survival) Up to 34% Increase
HR: 1.34
PPI use at treatment initiation adversely affects overall survival.
Good News: Patients using other antacid medications, such as famotidine or Rennie, did not show this adverse effect. The result was also independent of tumor MGMT methylation status, meaning it applied across patient groups.

A Roadmap for Physicians and Patients

The study's message is clear: "When alternatives may avoid harm, do not use the option that may cause it."

What to Avoid: In glioblastoma, particularly during corticosteroid treatment, routine use of omeprazole or pantoprazole as potent stomach protection should be avoided.
What to Prefer: If stomach protection is needed, agents that do not activate ALDH, such as H2 receptor blockers (e.g. famotidine) or simple antacid liquids/tablets should be preferred. They protect the stomach without undermining cancer treatment.
DROZDOGAN Academy Commentary

Sometimes medicine advances most by recognizing an error rather than discovering a drug. This study challenges routine oncology practice. It is unsettling that drugs long prescribed to prevent gastric bleeding may undermine patients' greatest battle against their tumors.

Yet the solution is simple: Change the medication. We retain stomach protection while changing the agent. Switching from omeprazole to alternatives such as famotidine is a simple, cost-neutral but potentially vital adjustment that could add months to a patient's life.

These findings suggest turning off prescription autopilot in glioblastoma care, asking whether each drug helps or harms the fight against the tumor.

Source:
  1. Le Rhun E, Sain D, Erridge SC, et al. Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of Randomized Clinical Trials. JAMA Network Open. 2025;8(11):e2545578. Published November 25, 2025.
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Stomach-Protecting Drugs May Adversely Affect Survival in Glioblastoma

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy